dc.contributor.author
Ostermann, Julia K.
dc.contributor.author
Witt, Claudia M.
dc.contributor.author
Reinhold, Thomas
dc.date.accessioned
2018-06-08T10:21:06Z
dc.date.available
2017-10-11T08:08:48.061Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20285
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-23589
dc.description.abstract
Objectives: This study aimed to provide a long-term cost comparison of
patients using additional homeopathic treatment (homeopathy group) with
patients using usual care (control group) over an observation period of 33
months. Methods: Health claims data from a large statutory health insurance
company were analysed from both the societal perspective (primary outcome) and
from the statutory health insurance perspective (secondary outcome). To
compare costs between patient groups, homeopathy and control patients were
matched in a 1:1 ratio using propensity scores. Predictor variables for the
propensity scores included health care costs and both medical and demographic
variables. Health care costs were analysed using an analysis of covariance,
adjusted for baseline costs, between groups both across diagnoses and for
specific diagnoses over a period of 33 months. Specific diagnoses included
depression, migraine, allergic rhinitis, asthma, atopic dermatitis, and
headache. Results: Data from 21,939 patients in the homeopathy group (67.4%
females) and 21,861 patients in the control group (67.2% females) were
analysed. Health care costs over the 33 months were 12,414 EUR [95% CI
12,022–12,805] in the homeopathy group and 10,428 EUR [95% CI 10,036–10,820]
in the control group (p<0.0001). The largest cost differences were attributed
to productivity losses (homeopathy: EUR 6,289 [6,118–6,460]; control: EUR
5,498 [5,326–5,670], p<0.0001) and outpatient costs (homeopathy: EUR 1,794
[1,770–1,818]; control: EUR 1,438 [1,414–1,462], p<0.0001). Although the costs
of the two groups converged over time, cost differences remained over the full
33 months. For all diagnoses, homeopathy patients generated higher costs than
control patients. Conclusion: The analysis showed that even when following-up
over 33 months, there were still cost differences between groups, with higher
costs in the homeopathy group.
en
dc.format.extent
13 Seiten
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
cost comparison
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
A retrospective cost-analysis of additional homeopathic treatment in Germany
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
PLoS ONE. - 12 (2017), 9, e0182897
dc.title.subtitle
Long-term economic outcomes
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0182897
dcterms.bibliographicCitation.url
http://doi.org/10.1371/journal.pone.0182897
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000028267
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000008940
dcterms.accessRights.openaire
open access
dcterms.isPartOf.issn
1932-6203